Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • APTO-253: Phase Ib hold

    Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO), Toronto, Ontario Product: APTO-253 (formerly LT-253, LOR-253) Business: Cancer Molecular target: Kruppel-like factor 4 (KLF4) (EZF) Description: Small molecule optimized …

    Published on 9/19/2016
  • CAP-1002: Completed Phase I/II enrollment

    Capricor Therapeutics Inc. (NASDAQ:CAPR), Beverly Hills, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: CAP-1002 Business: Cardiovascular Molecular target: NA Description: Allogeneic cardiosphere-…

    Published on 9/19/2016
  • ESN364: Completed Phase IIa enrollment

    Euroscreen S.A., Gosselies, Belgium Product: ESN364 Business: Endocrine/Metabolic Molecular target: Neurokinin 3 (NK3) receptor (TACR3) (NK3R) Description: Small molecule neurokinin 3 (NK3) receptor (TACR3; NK3R) …

    Published on 9/19/2016
  • Inecalcitol: Phase II started

    Hybrigenics S.A. (Euronext:ALHYG), Paris, France Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Inecalcitol Business: Cancer Molecular target: Vitamin D receptor (VDR) Description: Oral synthetic analog of vitamin …

    Published on 9/19/2016
  • IV APX001: Phase I started

    Amplyx Pharmaceuticals Inc., San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: IV APX001 Business: Infectious Molecular target: A. fumigatus GPI-anchored wall transfer protein 1 (A. fumigatus GWT1); C…

    Published on 9/19/2016
  • JTX-2011: Phase I/II started

    Jounce Therapeutics Inc., Cambridge, Mass. Product: JTX-2011 Business: Cancer Molecular target: Inducible T cell co-stimulator (ICOS) Description: Inducible T cell co-stimulator (ICOS) agonist antibody Indication: Treat…

    Published on 9/19/2016
  • LB1148: Phase II started

    Leading BioSciences Inc., San Diego, Calif. Product: LB1148 Business: Gastrointestinal Molecular target: Serine protease Description: Broad-spectrum serine protease inhibitor comprising tranexamic acid, polyethylene …

    Published on 9/19/2016
  • LGD-6972: Phase II started

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Product: LGD-6972 Business: Endocrine/Metabolic Molecular target: Glucagon receptor (GCGR) Description: Small molecule glucagon receptor (GCGR) antagonist …

    Published on 9/19/2016
  • RAAV2/2_ND4: Phase III amended

    GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Product: RAAV2/2_ND4 (GS010) Business: Ophthalmic Molecular target: NADH dehydrogenase subunit 4 (ND4) Description: Gene therapy product containing the human ND4 …

    Published on 9/19/2016
  • RAAV2/2_ND4: Phase III amended

    GenSight Biologics S.A. (Euronext:SIGHT), Paris, France Product: RAAV2/2_ND4 (GS010) Business: Ophthalmic Molecular target: NADH dehydrogenase subunit 4 (ND4) Description: Gene therapy product containing the human ND4 …

    Published on 9/19/2016
  • Vascepa icosapent ethyl: Phase III ongoing

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Product: Vascepa icosapent ethyl (formerly AMR101, Miraxion) Business: Cardiovascular Molecular target: NA Description: >96% pure ethyl ester of eicosapentaenoic acid (…

    Published on 9/19/2016
  • Viagenpumatucel-L: Phase Ib/II resumed

    Heat Biologics Inc. (NASDAQ:HTBX), Durham, N.C. Product: Viagenpumatucel-L (HS-110) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Vaccine comprising lung …

    Published on 9/19/2016
  • VX15/2503: Completed Phase II enrollment

    Vaccinex Inc., Rochester, N.Y. Product: VX15/2503 Business: Neurology Molecular target: Semaphorin 4D (SEMA4D) Description: Humanized mAb against semaphorin 4D (SEMA4D) Indication: Treat Huntingtons disease (HD) …

    Published on 9/19/2016
  • XmAb14045: Phase I started

    Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: XmAb14045 Business: Cancer Molecular target: CD3; Interleukin-3 (IL-3) receptor alpha (CD123) Description: …

    Published on 9/19/2016
  • ZW25: Phase I started

    Zymeworks Inc., Vancouver, B.C. Product: ZW25 Business: Cancer Molecular target: Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Description: Bispecific antibody targeting 2 epidermal growth factor …

    Published on 9/19/2016
  • AK001: Phase II started

    Allakos Inc., San Carlos, Calif. Product: AK001 Business: Inflammation Molecular target: Undisclosed Description: mAb targeting an inhibitory receptor on mast cells and eosinophils Indication: Treat nasal polyposis …

    Published on 9/12/2016
  • Aldoxorubicin: Completed Phase IIb enrollment

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 9/12/2016
  • Annexin V-128: Phase II started

    Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Product: Annexin V-128 (99mTc-rhAnnexin V-128) Business: Diagnostic Molecular target: NA Description: Single photon emission computed …

    Published on 9/12/2016
  • Annexin V-128: Phase II started

    Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Product: Annexin V-128 (99mTc-rhAnnexin V-128) Business: Diagnostic Molecular target: NA Description: Single photon emission computed …

    Published on 9/12/2016
  • AQX-1125: Phase III started

    Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Vancouver, B.C. Product: AQX-1125 Business: Genitourinary Molecular target: SH2-containing inositol 5-phosphatase (SHIP) Description: SH2-containing inositol 5-phosphatase (…

    Published on 9/12/2016
  • ARC-AAT: Phase II started

    Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-AAT Business: Hepatic Molecular target: Alpha-1 antitrypsin (AAT) (A1AT) (SERPINA1) Description: Unlocked nucleobase analog (UNA)-containing …

    Published on 9/12/2016
  • Asenapine maleate transdermal patch: Phase III started

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Product: Asenapine maleate transdermal patch (HP-3070 ) Business: Neurology Molecular target: NA Description: Transdermal tape formulation of the antipsychotic…

    Published on 9/12/2016
  • Cabozantinib: Phase III ongoing

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Ipsen Group (Euronext:IPN), Boulogne-Billancourt, France Product: Cabozantinib (Cometriq, Cabometyx) (XL184) Business: Cancer Molecular target: Vascular …

    Published on 9/12/2016
  • CAD106: Phase II started

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: CAD106 Business: Neurology Molecular target: Beta amyloid Description: Vaccine containing beta amyloid 1-6 peptide coupled to the virus-like particle Qb …

    Published on 9/12/2016
  • CERC-501: Completed Phase II enrollment

    Cerecor Inc. (NASDAQ:CERC), Baltimore, Md. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: CERC-501 (formerly LY2456302) Business: Neurology Molecular target: Kappa opioid receptor (KOR) (OPRK1) Description: …

    Published on 9/12/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993